Status:
COMPLETED
MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a clinical study to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients have Type 2 Diabetes Mellitus and have laboratory results that are within the values established by the study such as an Hemoglobin A1c (HbA1c) \>=7.5% and \<=11% and a Fasting Plasma Glucose (FPG) \>=130 mg/dL and \<=280 mg/dL
- Exclusion Criteria :
- Patients have Type 1 Diabetes Mellitus or required insulin therapy within the past 12 months
Exclusion
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
530 Patients enrolled
Trial Details
Trial ID
NCT00289848
Start Date
March 1 2006
End Date
March 1 2007
Last Update
June 15 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.